Preclinical News and Research

RSS

FINGERS-7B to eradicate Alzheimer's symptoms

Alzheimer's disease is best addressed as early as possible, ideally before symptoms become apparent. To enable early, accurate risk prediction both for individuals and whole populations, a team of AI researchers, physicians, and scientists centered at MIT has released FINGERS-7B, the first AI foundation model built to make Alzheimer's preventable.

28 Apr 2026

Three cognitive trajectories identified in preclinical Alzheimer’s disease

Cognitive decline in Alzheimer's disease differs substantially from one person to the next and is not well predicted by existing medical tests.

27 Apr 2026

New immune mapping tool reveals how lung cancer reshapes immune cells

Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors.

27 Apr 2026

Estrogen loss after menopause impacts heart health through gene regulation

Virginia Tech scientists at the Fralin Biomedical Research Institute say the increased risk of cardiovascular disease after menopause may stem not only from declining hormone levels, but also from how those changes influence gene activity.

27 Apr 2026

Repurposed drugs may provide safer treatments for aggressive childhood leukemia

Three clinically available drugs could pave the way for safer and more effective treatments for one of the most aggressive forms of childhood leukaemia, a new study suggests.

27 Apr 2026

ISSCR urges NIH to continue support human embryonic stem cell research

The International Society for Stem Cell Research (ISSCR) has submitted a formal response to a Request for Information (RFI) issued by the National Institutes of Health (NIH) regarding its pause on new submissions to the NIH Human Embryonic Stem Cell (hESC) Registry and considerations to reduce reliance on hESCs in federally supported research.

25 Apr 2026

Scientists identify STING switch driving inflammation in Alzheimer’s disease

The brain has its own immune system, which detects threats and mounts a defense. A growing body of evidence has shown that in Alzheimer's disease, those immune cells are chronically overactivated, causing inflammation that damages the connections between brain cells.

24 Apr 2026

New strategy boosts natural killer cells to fight cancer

Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense.

24 Apr 2026

"Domino" heart valves from diseased organs could save thousands of children

A surgical innovation called partial heart transplantation could transform care for children with severe heart valve disease, allowing for thousands of additional valve transplants each year, according to a presentation delivered today by Joseph Turek, MD, PhD, at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions.

24 Apr 2026

Antisense oligonucleotides reverse rare neurodevelopmental disorder in preclinical models

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical models. ASOs are short synthetic nucleic acid strands that target specific messenger RNA.

22 Apr 2026

Experimental drug kills aggressive breast cancer by toxic fat buildup

An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice.

22 Apr 2026

Global experts highlight new strategies to target human aging

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in human aging (12th ARDD meeting, 2025)."

22 Apr 2026

Pinecone-inspired conduit enables suture-free repair of nerve injuries

As the authors detail, PNI is a prevalent neurological condition that often causes permanent sensory and motor dysfunction, severely impairing patient's quality of life.

21 Apr 2026

Cognitive decline may signal heart trouble years before a cardiovascular event

In a large ASPREE and ASPREE-XT nested case-control study of older adults without prior cardiovascular disease, people who later experienced a CVD event showed faster cognitive decline beginning roughly 3 to 8 years before the event. Processing speed declined earliest, suggesting that subtle cognitive changes may emerge well before overt cardiovascular disease.

21 Apr 2026

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last visit (LPLV) has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.

From AlzeCure Pharma AB 21 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Age shapes melanoma progression and immune response

Cancer risk increases with age and is often more aggressive and difficult to treat in older adults. However, fewer than 10% of mouse studies use aged animals, with most relying on mice roughly equivalent to humans in their early 20s.

17 Apr 2026

Obesity, GLP-1s, and metabolic care

An interview with Professor Thomas Forst, Chief Medical Officer, hVIVO

From hVIVO 17 Apr 2026

Epigenetic changes allow cancer cells to shift identity and survive drugs

Cancer drugs are designed to shut tumors down. But sometimes, in the very act of attacking a tumor, treatment can also help a small fraction of cancer cells become harder to kill. A new study from researchers at the Institute for Systems Biology (ISB) shows that cancer cells may begin escaping therapy much earlier - as the therapy itself triggers a stress response that drives some cancer cells into a temporary drug-tolerant state.

16 Apr 2026

New lab-grown organoids accurately mimic pediatric brain tumor biology

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026